Stay updated with breaking news from Cingulate Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build
DelveInsight's, Attention Deficit Hyperactivity Disorder Pipeline Insight 2023 report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Attention Deficit Hyperactivity...
MIAMI BEACH, Fla. — Administration of Qelbree for up to 1 year showed similar safety, efficacy and tolerability profiles seen in shorter trials with improvement in ADHD symptoms and executive function, according to a study presented here. “The world needs more nonstimulants for ADHD,” Andrew J. Cutler, MD, associate clinical professor in the department of psychiatry, SUNY
Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended... | March 31, 2023
The metro’s field of venture capital-backed companies is getting more crowded — their payrolls swelling with new employees — amid a bounce-back from the global pandemic and new signals of Kansas City’s momentum, according to data in a new report from Startland News.